Ascelia Pharma AB (publ) (STO:ACE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 375.23M -24.1% |
| Revenue (ttm) | n/a |
| Net Income | -70.90M |
| EPS | -0.59 |
| Shares Out | 133.54M |
| PE Ratio | n/a |
| Forward PE | 14.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 438,906 |
| Open | 2.800 |
| Previous Close | 2.785 |
| Day's Range | 2.755 - 2.875 |
| 52-Week Range | 2.530 - 5.230 |
| Beta | 0.90 |
| Analysts | n/a |
| Price Target | 5.60 (+99.29%) |
| Earnings Date | Aug 20, 2026 |
About Ascelia Pharma AB
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in M... [Read more]
Financial Performance
Financial StatementsNews
Ascelia Pharma AB Transcript: ABGSC Investor Days
Major milestones are approaching with an FDA decision on Orviglance expected in early July and active partnering discussions underway. Orviglance targets a significant unmet need in liver imaging for cancer patients with renal disease, supported by strong clinical data and orphan drug exclusivity.
Q1 2026 Ascelia Pharma AB Earnings Presentation Transcript
Q1 2026 Ascelia Pharma AB Earnings Presentation Transcript
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 saw steady operating losses and a strengthened cash position after a SEK 20 million raise. Orviglance is on track for FDA approval in July, with strong clinical data and active partnership discussions. Market trends favor non-gadolinium agents, supporting a positive outlook.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q1 2026
Q1 2026 saw progress toward FDA approval and commercialization of Orviglance, with strong clinical data and an extended cash runway into 2027 after a SEK 20 million share issue. Oncoral remains in the pipeline with phase II plans in gastric cancer.
Ascelia Pharma AB Quarterly report: Q1 2026
Ascelia Pharma AB has published its Q1 2026 quarterly earnings report on May 12, 2026.
Ascelia Pharma AB Slides: Q1 2026
Ascelia Pharma AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 12, 2026.
Ascelia Pharma AB Transcript: DNB Carnegie Healthcare Seminar 2026
Orviglance, a manganese-based liver MRI agent for patients with severe renal disease, is under FDA review with a July 3 PDUFA date and strong Phase 3 data. Commercialization will rely on partnerships, and the company is also advancing Oncoral, an oral irinotecan, into further development.
Ascelia Pharma AB Earnings Call Transcript: Q4 2025
Lead program Orviglance is in FDA review with a decision expected by July, targeting a significant unmet need in liver imaging for cancer patients with severe renal impairment. Financials show a SEK 16 million Q4 loss and SEK 50 million cash, with partnership discussions and launch preparations progressing well.
Ascelia Pharma AB Annual report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 annual report on February 6, 2026.
Ascelia Pharma AB Quarterly report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 quarterly earnings report on February 6, 2026.
Ascelia Pharma AB Slides: Q4 2025
Ascelia Pharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 6, 2026.
Ascelia Pharma AB Earnings Call Transcript: Q4 2025
Orviglance is on track for FDA approval in July 2026, targeting an $800M global market for liver MRI contrast in cancer patients with severe kidney impairment. Q4 saw a SEK 16M operating loss, SEK 15M in liquid assets, and ongoing partnering discussions for commercialization.
Ascelia Pharma AB Annual report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 annual report on February 5, 2026.
Ascelia Pharma AB Quarterly report: Q4 2025
Ascelia Pharma AB has published its Q4 2025 quarterly earnings report on February 5, 2026.
Ascelia Pharma AB Slides: Q4 2025
Ascelia Pharma AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 5, 2026.
Ascelia Pharma AB Transcript: ABGSC Investor Days
The company is advancing Orviglance, a gadolinium-free liver MRI agent for patients with severe renal impairment, with FDA approval expected by July 3rd. Extensive clinical data and strong market research support its differentiation and commercial potential, while partner discussions and medical community engagement are ongoing.
Ascelia Pharma AB Slides: ABGSC Investor Days
Ascelia Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on December 4, 2025.
Ascelia Pharma AB Transcript: DNB Carnegie Småbolagsdag
A novel manganese-based imaging agent for liver cancer is nearing FDA approval, offering a safer alternative to gadolinium for patients with kidney issues. Clinical trials show improved detection of small lesions and a strong safety profile, with commercialization plans underway.
Ascelia Pharma AB Earnings Call Transcript: Q3 2025
NDA for Orviglance submitted, targeting FDA approval for liver MRI in high-risk patients. SEK 30M raised and convertibles converted, extending runway into Q4 next year. Focus remains on securing a commercialization partner and preparing for a U.S. launch.
Ascelia Pharma AB Quarterly report: Q3 2025
Ascelia Pharma AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Ascelia Pharma AB Slides: Q3 2025
Ascelia Pharma AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.
Ascelia Pharma AB Earnings Call Transcript: Q3 2025
OrbiGlans NDA was submitted to the FDA, with approval expected by July 2026, targeting a $800M market for liver imaging in cancer patients with impaired kidney function. Financials show a SEK 15M Q3 loss, SEK 72M in cash, and a strengthened balance sheet after recent financing.
Ascelia Pharma AB Quarterly report: Q3 2025
Ascelia Pharma AB has published its Q3 2025 quarterly earnings report on November 5, 2025.